Wolfgang Baiker
Direktor/Vorstandsmitglied bei PhotonPharma, Inc.
Profil
Wolfgang Baiker is currently a Director at Boehringer Ingelheim RCV GmbH & Co. KG and PhotonPharma, Inc., as well as a Venture Partner at Wellington Partners GmbH.
He previously served as President & Chief Executive Officer at Boehringer Ingelheim Pharmaceuticals, Inc. from 2018 to 2020, Chief Executive Officer at AdrenoMed AG in 2021 to 2022, and Director-Operation & Biopharmaceuticals at Boehringer Ingelheim GmbH from 2013 to 2016.
Baiker holds an MBA from Pace University, a doctorate from the University of Louisiana at Monroe, an undergraduate degree from Ruhr-Universität Bochum, and another doctorate from Universität Ulm.
Aktive Positionen von Wolfgang Baiker
Unternehmen | Position | Beginn |
---|---|---|
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Private Equity Investor | 01.01.2016 |
Boehringer Ingelheim RCV GmbH & Co. KG
Boehringer Ingelheim RCV GmbH & Co. KG BiotechnologyHealth Technology Boehringer Ingelheim RCV GmbH & Co. KG develops and supplies biotherapeutic proteins, plasmid DNA and antibody fragments. The company was founded in 1885 by Albert Boehringer and is headquartered in Vienna, Austria. | Direktor/Vorstandsmitglied | - |
PhotonPharma, Inc.
PhotonPharma, Inc. BiotechnologyHealth Technology PhotonPharma, Inc. is a company that is developing a personalized therapeutic cancer vaccine called Innocell. The company is based in Fort Collins, CO, at the Research Innovation Center of Colorado State University. The vaccine is designed using autologous tumor tissue and a photochemical inactivation platform that uses riboflavin and UV light to render tumor cells incapable of replication while still being able to metabolize, express proteins, present antigen, and stimulate immune recognition and response mechanisms. The company has demonstrated the ability of this technology to prevent metastatic tumor formation, reduce the growth of tumors, and stimulate cellular immune response pathways in preclinical development animal models. The company was founded in 2018 by Raymond Goodrich, and the CEO is Alan S. Rudolph. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Wolfgang Baiker
Unternehmen | Position | Ende |
---|---|---|
AdrenoMed AG
AdrenoMed AG Pharmaceuticals: MajorHealth Technology AdrenoMed AG develops a drug to decrease mortality in severe sepsis. The company was founded by Bernd Wegener, Gerald Heinz Möller and Andreas Bergmann in 2009 and is headquartered in Berlin, Germany. | Vorstandsvorsitzender | 15.03.2022 |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Vorstandsvorsitzender | 31.07.2020 |
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Geschäftsführer | 04.08.2016 |
Ausbildung von Wolfgang Baiker
Pace University | Masters Business Admin |
University of Louisiana at Monroe | Doctorate Degree |
Ruhr-Universität Bochum | Undergraduate Degree |
Universität Ulm | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 6 |
---|---|
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Finance |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Health Technology |
Boehringer Ingelheim RCV GmbH & Co. KG
Boehringer Ingelheim RCV GmbH & Co. KG BiotechnologyHealth Technology Boehringer Ingelheim RCV GmbH & Co. KG develops and supplies biotherapeutic proteins, plasmid DNA and antibody fragments. The company was founded in 1885 by Albert Boehringer and is headquartered in Vienna, Austria. | Health Technology |
PhotonPharma, Inc.
PhotonPharma, Inc. BiotechnologyHealth Technology PhotonPharma, Inc. is a company that is developing a personalized therapeutic cancer vaccine called Innocell. The company is based in Fort Collins, CO, at the Research Innovation Center of Colorado State University. The vaccine is designed using autologous tumor tissue and a photochemical inactivation platform that uses riboflavin and UV light to render tumor cells incapable of replication while still being able to metabolize, express proteins, present antigen, and stimulate immune recognition and response mechanisms. The company has demonstrated the ability of this technology to prevent metastatic tumor formation, reduce the growth of tumors, and stimulate cellular immune response pathways in preclinical development animal models. The company was founded in 2018 by Raymond Goodrich, and the CEO is Alan S. Rudolph. | Health Technology |
AdrenoMed AG
AdrenoMed AG Pharmaceuticals: MajorHealth Technology AdrenoMed AG develops a drug to decrease mortality in severe sepsis. The company was founded by Bernd Wegener, Gerald Heinz Möller and Andreas Bergmann in 2009 and is headquartered in Berlin, Germany. | Health Technology |